(Q36521880)

14 August 2017

1 reference

title

Update on daptomycin: the first approved lipopeptide antibiotic (English)

1 reference

14 August 2017

0 references

3

Joseph L Kuti

1 reference

14 August 2017

4

David P Nicolau

1 reference

14 August 2017

Su Young Lee

1

1 reference

14 August 2017

Hong Wei Fan

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

10

1 reference

14 August 2017

page(s)

1381-1397

1 reference

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin: a novel agent for Gram-positive infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin - a novel antibiotic against Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin: a cyclic lipopeptide antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Iturins, a special class of pore-forming lipopeptides: biological and physicochemical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Population pharmacokinetics of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Moderate liver impairment has no influence on daptomycin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vivo pharmacodynamic activity of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vivo synergy of daptomycin plus a penicillin agent for MRSA?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Daptomycin cure after cefazolin treatment failure of Methicillin-sensitive Staphylococcus aureus (MSSA) tricuspid valve acute bacterial endocarditis from a peripherally inserted central catheter (PICC) line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

Once-daily dosing in dogs optimizes daptomycin safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1381

10.1517/14656566.7.10.1381

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference